- CMTA and ToolGen Announce CMT1A CollaborationCMTA and ToolGen Announce Collaboration to Develop Potential Treatment for CMT1A Using Gene Therapy (Glenolden, PA, October 7, 2021) The Charcot–Marie–Tooth Association (CMTA), the largest philanthropic funder of CMT research worldwide, and ToolGen, a biotechnology company ...Read more ...
- CMTA and Addex Announce CMT1A CollaborationCMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A Addex Therapeutics is a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development. CMTA and Addex have formed a ...Read more ...
- Pete Foley Joins CMTA Board of DirectorsThe Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of Pete Foley to its Board of Directors.Read more ...
- CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical TrialsCMTA-STAR announced $1.1 million in grants March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2ARead more ...
- CMTA and Pharnext Enter Biomarker Research CollaborationCollaboration focused on identifying and characterizing key biomarkers in Charcot-Marie-Tooth disease Type 1ARead more ...